BriaCell Therapeutics Corp. (NASDAQ:BCTX) Short Interest Up 245.7% in December

BriaCell Therapeutics Corp. (NASDAQ:BCTX) was the target of a large growth in short interest in the month of December. As of December 15th, there was short interest totalling 2,380,000 shares, a growth of 245.7% from the November 30th total of 688,400 shares. Based on an average daily trading volume, of 2,490,000 shares, the short-interest ratio is currently 1.0 days. Currently, 6.0% of the shares of the company are sold short.

BriaCell Therapeutics Trading Down 4.1 %

BriaCell Therapeutics stock traded down $0.02 during midday trading on Thursday, reaching $0.52. 990,932 shares of the stock traded hands, compared to its average volume of 1,628,954. The firm has a fifty day moving average price of $0.78 and a two-hundred day moving average price of $0.83. BriaCell Therapeutics has a fifty-two week low of $0.46 and a fifty-two week high of $5.97. The firm has a market cap of $22.45 million, a price-to-earnings ratio of -0.44 and a beta of 1.46.

BriaCell Therapeutics (NASDAQ:BCTX) last issued its quarterly earnings data on Monday, December 16th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.14). Analysts anticipate that BriaCell Therapeutics will post -1.01 earnings per share for the current year.

Institutional Investors Weigh In On BriaCell Therapeutics

A hedge fund recently bought a new stake in BriaCell Therapeutics stock. Vontobel Holding Ltd. purchased a new position in BriaCell Therapeutics Corp. (NASDAQ:BCTX) in the third quarter, according to its most recent disclosure with the SEC. The institutional investor purchased 80,000 shares of the company’s stock, valued at approximately $99,000. Vontobel Holding Ltd. owned 0.44% of BriaCell Therapeutics at the end of the most recent quarter. Institutional investors and hedge funds own 15.42% of the company’s stock.

Analyst Ratings Changes

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $15.00 target price on shares of BriaCell Therapeutics in a research report on Thursday, December 12th.

BriaCell Therapeutics Company Profile

BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer.